Citations

Clear

3138 citation(s) found for "Smith, C".

Variants in genes regulating thiamine metabolism in children in the Lao Thiamine study
Nunez, Kristin Cardiel , Smith, Taryn J. , Kounnavong, Sengchanh , Thacher, Tom D. , Fischer, Philip R. , Hess, Sonja Y. , Hess, Sonja Y , Smith, Taryn J , Kounnavong, Sengchanh , Thacher, Thomas D , Fischer, Philip R , Cardiel Nunez, Kristin E , Hess, Sonja Y.

Mayo Clinic

Paediatrics and International Child Health | May 27, 2026 | Volume: 46 | Issue: 1-2 | Pages: 34-39

10.1080/20469047.2026.2657620 | PMID 42192095 Get It

A long-term image-derived AI-based risk model for primary prevention of breast cancer in individuals at high risk
Eriksson, Mikael , Czene, K, Scott, C, Stoddard, Shawn, Smith, Hugh, Hall, Per , Vachon, C, Scott, Christopher G. , Vachon, Celine M. , Czene, Kamila , Czene, Kamila , Scott, Christopher , Vachon, Celine M. , Hall, Per N , Eriksson, Mikael , Stoddard, Shawn M.

Mayo Clinic

Science Translational Medicine | May 20, 2026 | Volume: 18 | Issue: 850 | Pages: No page available

10.1126/scitranslmed.ady7414 | PMID 42160452 Get It

Image-derived artificial intelligence (AI) risk models have shown promise in short-term risk assessment for improving breast cancer (BC) screening. No image-derived long-term AI risk model for primary prevention has been developed and externally validated. Individuals aged 31 to 94 years were recruited between 2010 and 2020 in two population-based case cohorts (Olmsted County, Minnesota, US, and KARMA, Sweden) and one hospital-based case-control study (EMBED, Atlanta, US). Median follow-up in the case cohorts was 10 years, with BCs diagnosed through June 2022. Additional validation was performed in EMBED with 3-year follow-up. An AI risk model was developed in Sweden, and we report independent validation in Olmsted/KARMA/EMBED. Absolute 10-year risks were estimated at study entry. Time-dependent discriminatory performance [AUC( t )] and expected-to-observed events (E/O) were estimated. Comparisons were performed with clinical risk tools and the image-based Mirai tool. Across Olmsted/KARMA, 8696 individuals (mean age, 54.4±10.6) and 1633 individuals with incident BC (mean age, 57.0±10.6) were included. Average 10-year risks were 3.83 and 3.14%, and E/O ratios were 0.99 and 0.99. Ten-year AUC( t ) for invasive BCs were 0.72 in Olmsted and 0.72 in KARMA. Similar discriminatory results were observed in EMBED. Our AI risk tool performed significantly better than Mirai in Olmsted/KARMA/EMBED. In KARMA, in the top 10% of high-risk individuals, the AI risk tool predicted 33% of BCs compared with 23%/20%/24% predicted by Tyrer-Cuzick-v8/BCSC-v3/Mirai (all P < 0.01). The 10-year image-derived AI risk model showed significantly higher performance than clinical risk models and Mirai in diverse populations, supporting its clinical potential for primary prevention.
Immune checkpoint inhibitor-associated lymphocytic colitis in a patient with metastatic melanoma
Matar, Reem , Zeinah, Khalid Abu, Modi, Tanish , DUCHARME-SMITH, ALLISON, Abu Zeinah, Khalid, Matar, Reem

Mayo Clinic

BMJ Case Reports | May 19, 2026 | Volume: 19 | Issue: 5 | Pages: e270566

10.1136/bcr-2025-270566 | PMID 42156103 Get It

We describe the case of a man in his 60s with metastatic melanoma on encorafenib/binimetinib and nivolumab/relatlimab, with a history of immune checkpoint inhibitor (ICI)-induced acute interstitial nephritis, who presented with acute-onset nausea, vomiting and profuse watery diarrhoea. Investigations excluded infectious causes, and flexible sigmoidoscopy with biopsy demonstrated lymphocytic colitis. His symptoms persisted despite discontinuation of Braftovi-Mektovi (BRAF–MEK) therapy and required escalation of corticosteroid therapy and budesonide initiation. This case highlights the diagnostic challenges of differentiating ICI-mediated colitis from adverse events of targeted therapy and underscores the importance of endoscopic and histological confirmation in guiding treatment.
Resolving inflammatory bowel disease risk variants to genes and cell types
Zhang, Rui, Gettler, Kyle , Haritunians, Talin , Cleynen, Isabelle , Stevens, Christine R , Zhang, Qian , Tastad, Christopher, Medici, Catalina, Abreu, María T. , Achkar, Jean-Paul, Ahmad, Tariq, Bernstein, Charles, Brooks, Johanne , Bujanda, Luis, Butterworth, Jeffrey, Clark, Katie, Cummings, F, Buono, Joanne Del, Foley, Stephen, Franchimont, Denis , Hancock, L, Hart, Ailsa, Hooper, Patricia, Jarvis, Mark , Johnston, EL, Kemp, Cheryl, Kennedy, Nick, Lewis, James D. , Li, Andy, Louis, Édouard , Moayyedi, Paul, Moran, G , Newman, Bill, Oglesby, Arabis, Pekow, Joel, Perez, Kate J., Pollok, R, Radford-Smith, Graham , Raffals, L, Raine, Tim, Ramadas, Arvind, Ramakrishnan, S., Reinisch, Walter , Satsangi, Jack, Selinger, Christian, Shedwell, Sophy, Silverberg, Mark S. , Singh, Salil, Steel, Alan, Uhlig, Holm H. , Verma, Ajay, Weersma, Rinse K. , Xavier, Ramnik, Parkes, M, Lee, James C. , McGovern, D, Anderson, Carl A. , Lee, James , Raine, Tim , Zhang, Rui , Haritunians, Talin , Raine, Tim , Anderson, Carl A , Fachal, Laura , Cleynen, Isabelle , Stevens, Christine R. , Zhang, Qian , Tastad, Christopher , Do, Ron , Achkar, Jean–Paul , Ahmad, Tariq , Kok, Klaartje Bel , Butterworth, Jeffrey R., Cummings, Fraser , D’Amato, Mauro , Duerr, Richard H , Ellinghaus, David , Franchimont, Denis , Franke, André , Hart, Ailsa , Hooper, Patricia, Irving, Peter Miles , Julià, Antonio , Kennedy, Nicholas Alexander , Kupcinskas, Juozas , Latiano, Anna , Lewis, James D , McLaughlin, John , Moayyedi, Paul , Mowat, Craig , Newberry, Rodney D. , Perez, Kate J, Prescott, Natalie , Radford‐Smith, Graham L , Raffals, Laura E. , Reinisch, Walter , Rogler, Gerhard , Sands, Bruce E , Satsangi, Jack, Scharl, Michael , Schreiber, Stefan , Sebastian, Shaji , Selinger, Christian P. , Steed, Helen , Vermeire, Séverine , Halfvarson, Jonas , Daly, Mark J. , Lamb, Christopher A , Huang, Hailiang , McGovern, Dermot P.B. , Rioux, John D. , Cho, Judy H , Zhang, Rui

Mayo Clinic

No container title available | May 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.13.26352926 Get It

Abstract Inflammatory bowel diseases (IBD), principally Crohn’s disease (CD) and ulcerative colitis (UC), are common chronic disorders involving inflammation and often progressive tissue damage. Genome-wide association studies have mapped many risk signals, but the causal variants, effector genes and relevant cellular contexts remain difficult to resolve, limiting mechanistic interpretation and therapeutic translation. Here we performed a multi-ancestry GWAS meta-analysis of 125,992 individuals with IBD and more than 1.2 million controls, identifying 619 independent association signals (374 novel) at 420 IBD regions that account for 77–80% of SNP-based heritability. Fine-mapping resolved 81 high-confidence variants, 41 not previously reported. Although most signals were shared between CD and UC, 39% showed IBD subtype specificity, with UC signals showing stronger enrichment in functional annotations from intestinal epithelial, secretory and enteroendocrine cells, and CD showing stronger genetic correlations with circulating inflammatory biomarkers, including C-reactive protein and glycoprotein acetylation. Latent causal modelling supported a causal effect of decreased high-density lipoprotein on CD risk. By integrating bulk and single-cell eQTL and pQTL resources using colocalisation and Mendelian randomisation, together with coding-variant evidence from exome sequencing, we prioritised 664 candidate effector genes across 341 signals, including 390 newly implicated IBD genes, revealing new biological mechanisms and candidate therapeutic targets supported by human genetics.
A28-06 Sex Differences in Acute Pulmonary Embolism Outcomes Among African American Patients With Sickle Cell Disease: A National Estimate
Singh, N, Ramesh, A, Pathak, K, Pathak, D, Savani, K, Dhaliwal, K S, Ramphul, K

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.6268 Get It

Abstract Introduction Sickle cell disease (SCD) disproportionately affects African Americans(AA), comprising over 90% of cases. Acute pulmonary embolism (APE) is a serious complication in SCD patients due to increased thromboembolic risk from chronic inflammation, endothelial dysfunction, and hypercoagulability. Although recent studies have demonstrated sex-based differences in APE outcomes, data remain limited for SCD patients. We evaluated sex-based differences in outcomes among AA SCD patients with APE. Methods AA adults with SCD hospitalized for APE were queried from the 2016-2022 National Inpatient Sample. COVID-19 positive patients, patients younger than 18 years, and cases missing data were excluded. Demographics, treatment patterns, and in-hospital outcomes were compared between males and females using appropriate statistical tests with survey-weighted analysis. Results We studied 3635 SCD patients who were treated for APE, consisting of 60.66% (3635)females and 39.34%(2205) males. The overall mean age was 38.40 years, with no differences between the two sexes(mean age of 38.71 in males and 38.20 years in females, p = 0.620). While males reported a higher comorbidity burden with a Charlson Comorbidity Index(CCI) score of 1.03 (vs. 0.92 in females), it was not statistically significant(p = 0.345). In total, 23.43% of males and 22.68% of females had a prior history of PE(p = 0.815). Medicare constituted 31.82% of primary payers among males and 38.36% among females, while Medicaid and private insurance accounted for 32.52% and 24.83% of males, and 32.19% and 25.11% of females, respectively(p = 0.015). After adjusting for confounders, we found that females demonstrated higher odds of receiving transfusion to males. No statistically significant differences were seen for mortality, major cardiovascular complications including cardiac arrest, acute kidney injury, acute liver injury, ventricular tachycardia, or cardiogenic shock. In addition, treatment modalities such as mechanical ventilation, vasopressors or thrombolytic interventions(systemic thrombolysis, catheter-directed thrombolysis, mechanical thrombectomy) were comparable between males and females. We further did not find any differences in sepsis, bleeding events, acute ischemic stroke, or acute myocardial infarction(Table 1). Similarly, although females stayed longer(mean: 5.46 days vs. 4.90 days, p = 0.121), and had higher inflation-adjusted charges($61106 vs. $58810, p = 0.688), they were comparable. Conclusion Our study revealed that sex-based differences in outcome disparities among AA SCD patients admitted for APE are limited, with female transfusion requirements differing significantly, which warrants further investigation. This abstract is funded by: None
C54-21 Demographic and Mortality Differences Between Intensive Care and Non-intensive Care Admissions for Pseudomonas Sepsis in Chronic Lymphocytic Leukemia Patients
Ramesh, A, Singh, N, Savani, K, Pathak, D, Pathak, K, Dhaliwal, K S, Ramphul, K, Nookala, V, Cheriyath, P, Nookala, V

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.6240 Get It

Abstract Introduction Chronic Lymphocytic Leukemia(CLL) is the most common leukemia in adults in the United States. CLL patients are at higher risk of bacterial infections, and Pseudomonas aeruginosa is a notable pathogen. Limited data is available comparing the demographics and outcomes of pseudomonas sepsis in CLL. Our study aims to analyze the patient characteristics and mortality between intensive care unit (ICU) and non-ICU admissions for pseudomonas sepsis among CLL patients. Methods Adults with active CLL admitted with a primary diagnosis code of pseudomonas sepsis(ICD-10 code: A41.52) were identified via the National Inpatient Sample(NIS)(2016-2022), excluding COVID-19 cases. Admissions to ICU were estimated if the patients required mechanical ventilation , vasopressors or central venous catheter placement, as per prior NIS-based studies. The predictors of ICU admissions were identified using multivariable regression models, with further analyses focused on estimating the in-hospital mortality. All analysis incorporated adjustments for weight, cluster, and strata, as advised by the data source. Results A total of 1,650 admissions were identified, of which 335 (20.3%) required intensive care. The intensive care cohort was younger (mean age: 73.19 vs. 76.86 years), yet age was not a significant predictor for the need for intensive care. Significant racial disparities were observed, with Black patients demonstrating significantly higher odds of intensive care use than White patients. In contrast, Hispanic patients had comparable odds to White patients. Sex, weekend admission status, private insurance coverage versus Medicare, and income quartiles did not significantly impact intensive care utilization. Among comorbidities, liver cirrhosis and palliative care encounters predicted higher ICU admission rates. Paradoxically, hypertension was associated with lower odds. Other comorbidities showed no significant association with intensive care admission (Table 1). Intensive care patients demonstrated an in-hospital mortality rate of 40.91% versus 8.75% in non-intensive care patients (aOR: 6.690, 95% CI: 2.648-16.906, p &lt; 0.01). Furthermore, intensive care had a substantially greater resource utilization, longer stays (mean: 16.49 vs. 8.83 days, p &lt; 0.01) and markedly higher hospitalization charges (mean: $314,311 vs. $89,614, p &lt; 0.01). Conclusions Our study revealed that black race, comorbidities like liver cirrhosis and palliative care encounters were key predictors for ICU admissions. ICU utilization was associated with higher inpatient mortality, length of stay and hospitalization costs. These findings highlight the disparities and resource burden, and warrants strategic interventions to address them. This abstract is funded by: None
A67-11 Catheter-Directed Thrombolysis in Recurrent Versus First-Time Pulmonary Embolism: Comparing Complications, Mortality, and Readmissions
Singh, N, Dhillon, B, Pathak, K, Pathak, D, Savani, K, Dhaliwal, K S, Ramphul, K, Dhillon, Balkiranjit Kaur

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.5606 Get It

Abstract Introduction Catheter-directed thrombolysis (CDT) has emerged as a safer interventional option for acute pulmonary embolism (APE) compared to systemic thrombolysis, with reduced rates of hemorrhage and mortality. However, comparative outcomes between first-time and recurrent APE patients undergoing CDT remain inadequately documented. This study aims to compare complications, mortality, and readmissions following CDT in recurrent versus first-time PE to provide evidence-based guidance for treatment optimization. Methods We explored the 2016-2022 Nationwide Readmissions Database(NRD) for APE admissions treated with CDT and stratified our sample by history of prior pulmonary embolism. Our cases excluded patients with COVID-19 and those younger than 18 years. We compared differences in their demographics, in-hospital complications during the index admission, and 30-day readmission rates. Adjustments were made to account for the complex design of the NRD via STATA 18.0. Results Of 37,952 patients identified, 9.27% had a history of prior PE. The groups had comparable mean age, sex distribution, and hospital status, with varying comorbidities as shown in Tables 1a-1b. Patients with first-time PE were more likely to experience in-hospital complications including sepsis, transfusion requirement, invasive mechanical ventilation, shock, acute encephalopathy, acute kidney injury, and all-cause mortality during the index hospitalization(Table 2). However, hospital length of stay and charges were similar between groups(Table 1b). Following discharge, 30-day readmission rates were comparable (6.25% vs. 6.41% for first-time versus recurrent PE, respectively; hazard ratio 0.948, 95% CI 0.765-1.17, p = 0.626). Conclusion First-time APE patients who underwent CDT reported higher rates of various in-hospital complications, and all-cause mortality, despite having comparable 30-day readmission rates. There were certain limitations to our study, such as the lack of laboratory data, imaging findings, APE severity scores on admissions, and medication history. Prospective studies with detailed clinical parameters will help validate our findings and elucidate the different causes of death. This abstract is funded by: None
C27-12 Pneumocystis Jirovecii Pneumonia Among Cancer Patients: Comparing Outcomes Between Solid Tumors and Hematologic Malignancies
Singh, N, Ramesh, A, Savani, K, Pathak, K, Pathak, D, Dhaliwal, K S, Ramphul, K

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.4415 Get It

Abstract Introduction Pneumocystis jirovecii pneumonia (PJP) is a significant opportunistic infection in immunocompromised patients. While cancer patients experience significant immunosuppression that increases their susceptibility to PJP, outcomes of this infection stratified by specific tumor types remain poorly characterized. Methods This retrospective study identified adults with PJP and either solid or hematologic malignancies using the National Inpatient Sample (2016-2022). Exclusion criteria included age &lt;18 years, COVID-19 positivity, concurrent solid and hematologic malignancies, HIV positivity, or missing data. Baseline characteristics were compared between the two cancer groups. Multivariable regression analyses, adjusting for potential confounders, were conducted to estimate adjusted odds ratios for adverse events, treatments, and mortality. All analyses accounted for the complex survey design of the dataset. Results We found 11565 admissions involving PCP matching our selection, with 55.6%(6430) liquid and 44.4%(5135) solid cancers. Both groups contained an elderly population (mean age in solid: 64.25 years, vs. mean age in liquid: 63.36 years, p = 0.139), and mostly males( 51.32% of solid and 66.33% of liquid cancers, p &lt; 0.01). The adjusted Deyo Charlson Comorbidity Index Scores were also comparable(1.65 in solid vs. 1.55 in liquid cancers, p = 0.195). Majority of patients in both groups (73.97% of solid and 72.55% of liquid) were Whites(p = 0.155), insured via Medicare(52.98% of solid and 54.60% of liquid,p=0.580), and hospitalized at urban teaching centers(85.69% of solid and 87.17% of liquid, p = 0.341). Among patients with solid tumors, 32.03% were respiratory/thoracic cancers, 11.88% were breast cancers, 11.10% were gastrointestinal cancers. Among patients with hematologic malignancies, the most common diagnoses were lymphoma (48.4%) followed by leukemia (37.2%). Patients with hematologic malignancies recorded reduced rates of acute respiratory failure, mechanical ventilation requirements, and intubation. In contrast, no significant differences were observed between groups for cardiovascular complications including cardiac arrest and septic shock. Acute kidney injury odds were similarly comparable between the two cohorts(Table 1). Our analysis demonstrated significantly lower mortality in hematologic malignancy patients compared to solid tumor patients, but with longer lengths of stay (15.4 days vs 13.2 days) and higher hospital charges ($234,616 vs $188,792). Conclusions Our findings demonstrate that solid malignancies may pose a bigger threat to PJP outcomes as compared to hematological cancers, warranting further investigation to set up appropriate preventive strategies and treatment protocols. This abstract is funded by: None
B80-4-40 Myth or Reality: The July Effect on Robotic-assisted Thoracoscopic Lung Resection in Malignant Lung Neoplasms at Urban Teaching Centers
Ramesh, A, Singh, N, Savani, K, Pathak, K, Pathak, D, Dhaliwal, K S, Ramphul, K, Nookala, V, Cheriyath, P, Nookala, V

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.3814 Get It

Abstract Introduction Minimally invasive surgical techniques including Robotic-Assisted thoracoscopic surgery (RATS) have advanced the treatment of lung cancer and enhanced patient outcomes from early recovery to improved quality of life. The “July effect” hypothesizes that morbidity and mortality outcomes worsen during the beginning of academic year when new residents and fellows begin training. We investigated the impact of the same on outcomes of RATS among lung cancer patients. Methods Using the National Inpatient Sample (2016-2019), we identified adults(ages≥18 years) with lung cancer who underwent RATS(lobectomy/sublobar resection) at urban teaching centers(UTC). Patients were stratified by surgical timing: July-September versus other months. Multivariable logistic regression compared perioperative outcomes between groups, adjusting for confounders. Results We analyzed 25,480 RATS procedures, with 25.59% performed during July-September. Baseline characteristics were comparable between groups regarding sex, race (White, Hispanic), insurance type, comorbidity burden, and age; however, fewer Black patients underwent surgery during July-September (Table 1a). Multivariable logistic regression revealed no significant differences in perioperative outcomes between the July-September and other months of the year. Evaluated outcomes included thoracic complications like pneumonia (aOR 0.89, 95% CI 0.62-1.28, p = 0.526), pneumothorax (aOR 1.07, 95% CI 0.85-1.34, p = 0.583), air leak (aOR 0.98, 95% CI 0.79- 1.22, p = 0.873), respiratory failure (aOR 0.9, 95% CI 0.50-1.63, p = 0.729) , atelectasis (aOR 1.12, 95% CI 0.88-1.42, p = 0.372), thromboembolic events like pulmonary embolism (aOR 0.63, 95% CI 0.13-2.97, p = 0.557), deep venous thrombosis (aOR 1.01, 95% CI 0.65-1.57, p = 0.952), bleeding complications like transfusion (aOR 0.95, 95% CI 0.55-1.64, p = 0.866), hemothorax/hemoperitoneum/hematoma (aOR 0.58, 95% CI 0.22-1.52, p = 0.264), renal complications (aOR 1.00, 95% CI 0.32-3.17, p = 0.994), conversion to open surgery (aOR 0.53, 95% CI 0.11-2.47, p = 0.417), extended length of stay (&gt;7 days) (aOR 0.96, 95% CI 0.78-1.17, p = 0.667), and in-hospital mortality (aOR 0.57, 95% CI 0.21-1.50, p = 0.250)(Table 1b). Conclusions Our study suggested no “July effect” in the perioperative outcomes of RATS. This demonstrates the robust hospital support systems ensuring the safe transition of resident classes without affecting the patient care negatively. This abstract is funded by: None